

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Alain T. Luxembourg, Michael R. Jackson

and Per A. Peterson

Confirmation No.: 1342

Application No.: 10/785,472

Group Art Unit: 1644

Filing Date: February 23, 2004

Examiner: Francois P. Vandervegt

For: PURIFICATION OF ANTIGEN-SPECIFIC T CELLS

EXPRESS MAIL LABEL NO: EV670670587US

DATE OF DEPOSIT: October 6, 2005

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

In accordance with § 1.97(b), since this Information Disclosure Statement is
being filed either within three months of the filing date of the above-identified

	application, within three months of the date of entry into the national stage of						
	the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application,						
	before the mailing date of a first Office Action after the filing of request for						
	continued examination under § 1.114, no additional fee is required.						
	In accordance with § 1.97(c), this Information Disclosure Statement is being						
	filed after the period set forth in § 1.97(b) above but before the mailing date of						
	either a Final Action under § 1.116 or a Notice of Allowance under § 1.311						
	before an action that otherwise closes prosecution in the application, therefore:						
	Certification in Accordance with § 1.97(e) is attached; or						
	The fee of \$180.00 as set forth in § 1.17(p) is attached.						
\boxtimes	In accordance with § 1.97(d), this Information Disclosure Statement is being						
	filed after the mailing date of either a Final Action under § 1.113 or a Notice						
	of Allowance under § 1.311 but before, or simultaneously with, the payment						
	of the Issue Fee, therefore included are: Certification in Accordance with						
	1.97(e); and the submission fee of <u>\$180.00</u> as set forth in § 1.17(p).						
\boxtimes	Copies of reference numbers 1 - 2 listed on the attached Form PTO-1449 are						
	enclosed herewith.						
	Copies of reference numbers - on the attached Form PTO 1449						
	are not required to be submitted pursuant to 37 CFR § 1.98(a)(2)(i).						
	Copies of references - are not being submitted because they were						
	previously cited by or submitted to the U.S. Patent and Trademark Office						
	patent application number , filed for which a claim for priority						
	under 35 U.S.C. § 120 has been made in the instant application.						

DOCKET NO.: JJPR-0050 (ORT-1060-CON) - 3 - PATENT

The relevance of those listed references which are not in the English language is as follows:

There are no listed references which are not in the English language.

Please charge any deficiency or credit any overpayment to Deposit Account No.

23-3050. This form is submitted in duplicate.

Date: October 6, 2005

Phillip A. Singer

Registration No. 40,176

WOODCOCK WASHBURN LLP One Liberty Place - 46th Floor Philadelphia, PA 19103 Telephone: (215) 568-3100 Facsimile: (215) 568-3439

© 2005 WW

KET NO.: JJPR-0050 (ORT-1060-CON)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Alain T. Luxembourg, Michael R. Jackson,

Per A. Peterson

Confirmation No.: 1342

Application No.: 10/785,472

Group Art Unit: 1644

Filing Date: February 23, 2004

Examiner: Francois P. Vandervegt

For: PURIFICATION OF ANTIGEN-SPECIFIC T CELLS

EXPRESS MAIL LABEL NO: EV670670587US

DATE OF DEPOSIT: October 6, 2005

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

CERTIFICATION UNDER 37 CFR § 1.97(e)

In accordance with 37 CFR § 1.97(e), certification is hereby made that:

Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement.

No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the

filing of the information disclosure statement.

Date: October 6, 2005

Phillip A. Singer

Registration No. 40,176

Woodcock Washburn LLP One Liberty Place - 46th Floor Philadelphia PA 19103

Telephone: (215) 568-3100 Facsimile: (215) 568-3439



EXAMINER

<u> </u>	et 2						
For	rm P7	۲ O -	1449 Modified	Docket No. JJPR-0050 (ORT-0106-CON)	Application No. 10/785,472		
	Cite	d b	and Publications y Applicant heets if necessary)	Applicant Alain T. Luxembourg, Michael R. Jackson and Per A. Peterson			
			ent of Commerce rademark Office	Filing Date February 23, 2004	Group 1644		
				Confirmation No. 1342			
	OTE	IER	R DOCUMENTS (Inclu	iding Author, Title, Date, Pertinen	t Pages, Etc.)		
		1	Boog, Claire J. P. et al., "Specific immune responses restored by alteration in carbohydrate chains of surface molecules on antigen-presenting cells," <i>Eur. J. Immunol.</i> , 19, 1989 , 537-542				
		2	Marchal, Ingrid et al., "Glycoproteins from Insect Cells: Sialylated or Not?," <i>Biol. Chem.</i> , 2001 , 382, 151-159				

DATE CONSIDERED